Sandoz decision will encourage biosimilar PTAB proceedings
The Federal Circuit’s decision in Sandoz v Amgen will lead to biosimilar companies looking to use PTAB proceedings more to invalidate drug patents, because it is now harder for them to bring district court actions before filing biosimilar applications
The Federal Circuit’s Sandoz decision addressed when and how a party looking to launch a biosimilar product in the US can launch a lawsuit to challenge a brand company’s patents.
Sandoz had sued Amgen and Hoffman-La Roche to...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.